The present invention includes 16-HETE analogs which are agonists and antagonists
of 16-HETE. The compositions may be formulated in pharmaceutically acceptable formulations.
The invention also includes methods and products for inhibiting neutrophil adhesion
and neutrophil aggregation using the 16-HETE agonists. One method of the invention
involves the administration of a 16-HETE agonist in combination with a thrombolytic
agent to a patient suffering from, thromboembolic stroke.
